Trial Profile
Compare immunogenicity and reactogenicity of 2 formulations of GSK Biologicals' DTPa-HBV-IPV/Hib vaccine (new vs current) given in healthy infants. The DTPa-HBV-IPV vaccine (new formulation) will also be assessed in a 3rd group of subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary) ; DTaP-hepatitis B-poliovirus vaccine
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
- Focus Pharmacodynamics; Pharmacokinetics; Registrational
- Sponsors GlaxoSmithKline; GSK
- 16 Jan 2008 Status changed from in progress to completed.
- 01 Jun 2007 New trial record.